Gregory P. Hanson Sells 66,550 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CFO Gregory P. Hanson sold 66,550 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $0.96, for a total transaction of $63,888.00. Following the completion of the transaction, the chief financial officer now directly owns 478,365 shares in the company, valued at approximately $459,230.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

MabVax Therapeutics Holdings, Inc. (MBVX) opened at $0.87 on Friday. The company has a market cap of $20.45, a price-to-earnings ratio of -0.25 and a beta of 1.52. MabVax Therapeutics Holdings, Inc. has a twelve month low of $0.43 and a twelve month high of $3.57. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.80.

MabVax Therapeutics (NASDAQ:MBVX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.54) EPS for the quarter. equities research analysts expect that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. bought a new stake in shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned about 12.33% of MabVax Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.87% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3145538/gregory-p-hanson-sells-66550-shares-of-mabvax-therapeutics-holdings-inc-mbvx-stock.html.

About MabVax Therapeutics

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.